3rd Quarter - Amendment

TAKEDA PHARMACEUTICALS AMERICA, INC. for TAKEDA PHARMACEUTICALS AMERICA INC

Firm
Client
Income
—
Expenses
$510,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
3rd Quarter - Report Oct 3, 2011 $400,000 Replaced
3rd Quarter - Amendment Jan 19, 2012 $350,000 Replaced
3rd Quarter - Amendment (this page) Jan 19, 2012 $510,000 Yes

What was lobbied

8 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Importation issues; Preserve Access to Affordable Generics Act; S. 319 Pharmaceutical Market Access and Drug Safety Act;

LobbyistCovered position, as disclosed
ANDREA WILKINSON —

Contacted: Agency for Healthcare Research & Quality (AHRQ); Defense, Dept of (DOD); SENATE; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Treasury, Dept of; Health Resources & Services Administration (HRSA); Medicare Payment Advisory Commission (MedPAC)

Bills named: S. 319 (112th)

Budget/Appropriations BUD

Agriculture; Labor, HHS; Commerce and Homeland Security Departments Appropriation Bills; Continuing Resolution; Budget Control Act of 2011; Joint Committee on Deficit Reduction

LobbyistCovered position, as disclosed
ANDREA WILKINSON —

Contacted: Health Resources & Services Administration (HRSA); Defense, Dept of (DOD); Centers For Medicare and Medicaid Services (CMS); Agency for Healthcare Research & Quality (AHRQ); HOUSE OF REPRESENTATIVES; Treasury, Dept of; Medicare Payment Advisory Commission (MedPAC); SENATE; Food & Drug Administration (FDA)

Manufacturing MAN

Prescription Drug User Fee Act Reauthorization; FDA Sentinel Pilot; S. 319 Pharmaceutical Market Access and Drug Safety Act; H.R.2245, Preserving Access to Life-Saving Medications Act of 2011; DTC advertising; HR 1483 Drug Import Safety legislation; drug pedigree, supply chain/shortage issues; Safeguarding Americas Pharmaceuticals Act; counterfiet and serialization;

LobbyistCovered position, as disclosed
DEBORAH LYNN WALTER New —
ANDREA WILKINSON —

Contacted: Food & Drug Administration (FDA); Medicare Payment Advisory Commission (MedPAC); Centers For Medicare and Medicaid Services (CMS); Defense, Dept of (DOD); Treasury, Dept of; SENATE; HOUSE OF REPRESENTATIVES; Health Resources & Services Administration (HRSA); Agency for Healthcare Research & Quality (AHRQ)

Bills named: H.R. 2245 (112th), H.R. 1483 (112th), S. 319 (112th)

Taxation/Internal Revenue Code TAX

Implementaton of ACA Pharmaceutical fee; corporate tax reform, R&D tax credit extension; Debt commissions recommendations; Reid/Baucus Lundgren repeal of Patient Protection and Affordable Care Act; Innovate America Act; Ryan Roadmap; Debt and deficit negotiations; foreign tax reforms; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; S. 1577 R&D Credit Bill

LobbyistCovered position, as disclosed
ANDREA WILKINSON —

Contacted: Treasury, Dept of; Defense, Dept of (DOD); SENATE; Agency for Healthcare Research & Quality (AHRQ); Medicare Payment Advisory Commission (MedPAC); HOUSE OF REPRESENTATIVES; Health Resources & Services Administration (HRSA); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS)

Bills named: S. 1577 (112th), S. 1206 (112th), H.R. 2190 (112th)

Copyright/Patent/Trademark CPT

S. 23 Patent Reform Act of 2011; S. 27 Preserve Access to Affordable Generics; general patent settlement issues; HR 1249, America Invents Act; S. 968, the PROTECT IP Act

LobbyistCovered position, as disclosed
ANDREA WILKINSON —

Contacted: Defense, Dept of (DOD); Medicare Payment Advisory Commission (MedPAC); Agency for Healthcare Research & Quality (AHRQ); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); SENATE; Treasury, Dept of; HOUSE OF REPRESENTATIVES; Health Resources & Services Administration (HRSA)

Bills named: S. 27 (112th), H.R. 1249 (112th), S. 968 (112th), S. 23 (112th)

Health Issues HCR

General comparative effectiveness issues, health reform and the un/underinsured, chronic disease legislation (diabetes, mental health, obesity, CKD), value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; PCORI; Essential benefits package, ESRD bundling implementation; coverage gap, S. 371/HR741 Bill to prohibit authorized generics, Debt and Deficit negotiations

LobbyistCovered position, as disclosed
LAURA ELIZABETH CLINE —
DEBORAH LYNN WALTER —
ANDREA WILKINSON —

Contacted: Centers For Medicare and Medicaid Services (CMS); Health Resources & Services Administration (HRSA); Treasury, Dept of; Defense, Dept of (DOD); SENATE; Medicare Payment Advisory Commission (MedPAC); Agency for Healthcare Research & Quality (AHRQ); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Bills named: S. 371 (112th), H.R. 741 (112th)

Medicare/Medicaid MMM

340B-1 and AMP, Part D coverage gap discount program implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform; Value based Purchasing Program; End Stage Renal Disease final rules; TRICARE, HR 457 Medicare Decisions Accountability Act of 2011 (IPAB repeal), Medicare Evident Development and Coverage Ad Com.; Medicare Payment Advisory Commission; S. 31 Prescription Drug and Health Improvement Act; Debt and deficit negotiations S. 44 Medicare Prescription Drug Price Negotiation Act; CMS proposed Medicare Advantage; S 373 Fair Prescription Drug Competition Act; Ryan Roadmap; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; the Medicaid Improvement and State Empowerment Act; Academic Detailing;

LobbyistCovered position, as disclosed
LAURA ELIZABETH CLINE —
DEBORAH LYNN WALTER —
ANDREA WILKINSON —

Contacted: Defense, Dept of (DOD); Food & Drug Administration (FDA); Agency for Healthcare Research & Quality (AHRQ); HOUSE OF REPRESENTATIVES; Treasury, Dept of; Medicare Payment Advisory Commission (MedPAC); Centers For Medicare and Medicaid Services (CMS); Health Resources & Services Administration (HRSA); SENATE

Bills named: H.R. 2190 (112th), H.R. 457 (112th), S. 44 (112th), S. 1206 (112th), S. 31 (112th)

Medical/Disease Research/Clinical Labs MED

Regenerative Medicines Promotion Act; Gastrointestinal and Motility Disorders Research Enhancement Act (H.R. 2239); depression screening, end stage renal disease;

LobbyistCovered position, as disclosed
ANDREA WILKINSON —

Contacted: Defense, Dept of (DOD); Centers For Medicare and Medicaid Services (CMS); Agency for Healthcare Research & Quality (AHRQ); Health Resources & Services Administration (HRSA); SENATE; Treasury, Dept of; Medicare Payment Advisory Commission (MedPAC); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Bills named: H.R. 2239 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.